This monoclonal antibody has the generic name denosumab and is suitable for treating or preventing osteoporosis in post-menopausal women. The monoclonal antibody inhibits RANKL, a protein that activates osteoclasts to regenerate and remodel bone. By inhibiting RANKL, the drug helps reduce osteoclast activity, so less bone is broken down and the bones can rebuild themselves stronger. One injection provides results lasting about six months.